The company is consolidating its operations in Vadodara, with US headcount slashed by over 80 percent, labs reduced from four ...

Enliven Therapeutics (EVN) stock jumps as the company post initial early-stage trial data for its lead asset ELVN-001 in ...

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the deadliest brain cancers. By combining Tumor Treating Fields (TTFields), which ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Celcuity Inc. (NASDAQ:CELC) is one of the top ...

After a shaky start to 2025, the S&P 500 rallied to close out a third consecutive year of above-average gains for the index. The S&P 500 still finished the year up more than 16% ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Amber said that joining the Young Lives vs Cancer voice board, where patients and their families are offered the opportunity ...

A recent study highlights asciminib's effectiveness in treating newly diagnosed CML, showing promising molecular response rates and safety profiles. Fadi Haddad, MD, an assistant professor and ...

Fadi Haddad, MD, discusses the use of asciminib in patients with chronic myeloid leukemia. Watch part 1 of the interview here. In the second part of our interview with Fadi Haddad, MD, an assistant ...